Pharmacokinetics of cephalosporins in the neonate: a review

Gian Maria Pacifici
University of Pisa, Department of Neurosciences, Section of Pharmacology, Medical School, Pisa, Italy.

The aim of this work was to review the published data on the pharmacokinetics of cephalosporins in neonates to provide a critical analysis of the literature as a useful tool for physicians. The bibliographic search was performed for articles published up to December 3, 2010, using PubMed. In addition, the book Neofax: A Manual of Drugs Used in Neonatal Care by Young and Mangum was consulted. The cephalosporins are mainly eliminated by the kidneys, and their elimination rates are reduced at birth. As a consequence, clearance is reduced and t½ is more prolonged in the neonate than in more mature infants. The neonate’s substantial body water content creates a large volume of distribution (Vd) of cephalosporins, as these drugs are fairly water soluble. Postnatal development is an important factor in the maturation of the neonate, and as postnatal age proceeds, the clearance of cephalosporins increases. The maturation of the kidney governs the pharmacokinetics of cephalosporins in the infant. Clearance and t½ are influenced by development, and this must be taken into consideration when planning a cephalosporin dosage regimen for the neonate.

KEYWORDS: Cephalosporins; Pharmacokinetics; Neonate.

INTRODUCTION
Cephalosporins are the most common class of antibiotics used to treat bacterial infection. These drugs have proven to be safe, clinically effective, and easy to use. The expanded-spectrum cephalosporins (e.g., cefotaxime, ceftriaxone, and ceftazidime), either alone or in combination with other antibiotics, are the most common antibiotics used as initial empiric therapy for treating serious infections.

The first generation of cephalosporins has good activity against Gram-positive bacteria and relatively modest activity against Gram-negative bacteria. The second generation of cephalosporins has increased activity against Gram-negative microorganisms but tends to be much less active than the third-generation agents. The fourth generation of cephalosporins is particularly useful for the empirical treatment of serious infections in hospitalized patients when Enterobacteriaceae and pseudomonas are potential etiologies.

Cephalosporins are minimally toxic, with the exception of ceftriaxone, which displaces bilirubin from albumin and precipitates calcium, resulting in serious adverse effects. The aim of this paper was to review the literature on the kinetics of cephalosporins in the neonate and provide a critical analysis of the literature as a useful tool for physicians.

Bibliographic search
The bibliographic search was performed electronically, using PubMed to find articles published up to December 3, 2010. First, a Medline search was performed with the key words “pharmacokinetics of cephalosporins in neonates,” with the limit of “human”. Other Medline searches were performed with the key words “pharmacokinetics of ……… in neonates,” followed by the names of single cephalosporins. In addition, the book Neofax: A Manual of Drugs Used in Neonatal Care by Young and Mangum was consulted. The bibliographic search produced 37 original articles, four review articles and two book chapters. The publication years of this material ranged from 1977 to 2010.

RESULTS
The demographic data for the neonates and the pharmacokinetic parameters of different cephalosporins are presented in four tables. Information relative to the first-generation cephalosporin, cefazolin, and the second-generation cephalosporins, cefoxitin, and cefuroxime, is provided in Table 1. Table 2 summarizes the results relative to the third-generation cephalosporins. Table 3 shows the results relative to cephepine, a fourth-generation cephalosporin, and Table 4 shows the concentrations of various cephalosporins in the cerebrospinal fluid (CSF) and serum.

Clearance (Cl) is expressed in different units by different authors. This makes comparisons between studies difficult. To overcome this difficulty, Cl was converted into ml/min/kg. SD cannot be converted; therefore, Cl values are reported without SDs.
**First generation cephalosporin**

**Cefazolin.** The pharmacokinetics of cefazolin (Table 1) in 11 neonates were studied by Deguchi et al. There was marked interindividual variability in the distribution volume (Vd). This parameter ranged from 0.21 to 0.37 L/kg. The unbound fraction of cefazolin in neonatal plasma ranged from 0.22 to 0.83. The Vd of cefazolin highly correlated (r = 0.936; p < 0.001) with the unbound fraction of this drug.

Young and Mangum suggested administering 25 mg/kg of cefazolin every 8 to 12 h according to the neonate’s postmenstrual age and postnatal age. When the postmenstrual age is >45 weeks, the interval between doses should be six hours.

**Second-generation cephalosporins**

**Cefotaxime.** Regazzi et al studied the pharmacokinetics of cefotaxime in 15 neonates. Their reported kinetic parameters are summarized in Table 1. The half-life (t₁/₂) negatively correlated with postnatal age (r = −0.58; p < 0.05). Young and Mangum suggested administering 25 to 33 mg/kg cefotaxime every 8 or 12 h according to the neonates’ gestational age and postnatal age. With neonatal maturation, t₁/₂ decreased and CI increased. For brevity, Table 2 shows the two extremes of the cohort. In five patients with meningitis who received 50 mg/kg cefotaxime twice daily, the concentration of the drug was simultaneously measured in the CSF and serum 1 to 2 h after cefotaxime administration. The CSF and serum concentrations (mean ± SD) were 18.2 ± 7.4 and 38.6 ± 10.3 μg/ml, respectively. The CSF-to-serum ratio was 45 ± 12%.

McCracken et al compared the kinetic parameters of cefotaxime in two groups of neonates; the first had an average body weight of 1,103 g, and the second had an average body weight of 2,561 g (p < 0.0001). Vd and t₁/₂ were greater in the former than the latter group, whereas CI was greater in the latter group and AUC was not different in the two groups.

Cefotaxime is converted into desacetyl cefotaxime in the neonate, and the peak concentration of desacetyl cefotaxime is about one-tenth of that of cefotaxime. The t₁/₂ of desacetyl cefotaxime is 9.4 h in very low-body-weight neonates. After 50 mg/kg cefotaxime, 50 to 60% of the dose is excreted unchanged in the urine, and approximately 20% is excreted as desacetyl cefotaxime. The renal CI of cefotaxime is quantitatively more important than its metabolic CI. Gouyon et al observed that the t₁/₂ of cefotaxime was negatively correlated with gestational age (r = −0.8954; p < 0.01) and body weight (r = −0.8500; p < 0.01). In contrast, CI was positively correlated with gestational age (r = 0.7280; p < 0.02) and body weight (r = 0.8667; p < 0.02). The AUC of cefotaxime was negatively correlated with gestational age (r = −0.7950; p < 0.01), but it did not correlate with body weight.

One recent study examined cefotaxime in neonates undergoing extracorporeal membrane oxygenation (ECMO). Doses of 50 mg/kg of body weight twice a day (postnatal age <1 week), 50 mg/kg three times a day (postnatal age 1 to 4 weeks) or 37.5 mg/kg four times a day (postnatal age >4 weeks) were found to provide sufficient periods of supra-MIC concentrations to give adequate treatment of infants on ECMO.

Young and Mangum suggested intravenously administering 25 to 33 mg/kg of cefotaxime every 8 or 12 h.

---

### Table 1 - Demographic data of the studied neonates and pharmacokinetic parameters of first- and second-generation cephalosporins. Figures are the mean ± SD.

| Grup | Gestational age (wk) | Postnatal age (days) | Body weight (g) | No. of cases | Daily dose (mg/kg) | CI (ml/min/kg) | Vd (L/kg) | t₁/₂ (h) | Peak conc. (μg/ml) | Trough conc. (μg/ml) | Reference |
|------|----------------------|----------------------|-----------------|-------------|------------------|---------------|-----------|----------|------------------|---------------------|-----------|
| C. | 35 ± 3 | 9.4 ± 7.4 | 2,326 ± 943 | 11 | 30 | 0.80 | 0.28 ± 0.05 | na | na | na | 10 |
| Cefotaxime and cefuroxime – Second-generation cephalosporins | | | | | | | | | | | |
| Drug | Gestational age (wk) | Postnatal age (days) | Body weight (g) | No. of cases | Daily dose (mg/kg) | CI (ml/min/kg) | Vd (L/kg) | t₁/₂ (h) | Peak conc. (μg/ml) | Trough conc. (μg/ml) | Reference |
| Cefotaxime | 36 ± 4 | < 2 months | 2,404 ± 599 | 15 | 30 ± 3 | 4.5 | 0.50 ± 0.21 | 1.43 ± 0.53 | 69.8 ± 31.9 | na | 11 |
| Cefuroxime | na | < 3 weeks | < 1,000 > 4,000 | 104 | 10 ± 3 | na | na | 4.6 ± 0.7 | 24.2 ± 8.2 b | 6.4 ± 5.6 b | 12 |

na = not available.

Data obtained in 10 neonates.

Data obtained in 5 neonates.

---

### Table 2 - Summary of pharmacokinetic parameters of cefazolin, cefotaxime, and cefuroxime in neonates.

| Drug | Gestational age (wk) | Postnatal age (days) | Body weight (g) | No. of cases | Daily dose (mg/kg) | CI (ml/min/kg) | Vd (L/kg) | t₁/₂ (h) | Peak conc. (μg/ml) | Trough conc. (μg/ml) | Reference |
|------|----------------------|----------------------|-----------------|-------------|------------------|---------------|-----------|----------|------------------|---------------------|-----------|
| Cefazolin | 36 ± 4 | < 2 months | 2,404 ± 599 | 15 | 30 ± 3 | 4.5 | 0.50 ± 0.21 | 1.43 ± 0.53 | 69.8 ± 31.9 | na | 11 |
| Cefotaxime | na | < 3 weeks | < 1,000 > 4,000 | 104 | 10 ± 3 | na | na | 4.6 ± 0.7 | 24.2 ± 8.2 b | 6.4 ± 5.6 b | 12 |

### Data obtained in 10 neonates.

### Data obtained in 5 neonates.
Table 2 - Demographic data of the studied neonates and pharmacokinetic parameters of the third-generation cephalosporins. Figures are the mean ± SD unless otherwise stated.

### Cefotaxime – Third-generation cephalosporins

| Comment | Gestational age (wk) | Postnatal age (days) | Body weight (g) | No. of Cases | Daily dose (mg/kg) | AUC (µg.h/ml) | CL (ml/min/kg) | Vd (L/kg) | t1/2 (h) | Peak conc. (µg/ml) | Trough conc. (µg/ml) | Reference |
|---------|----------------------|----------------------|-----------------|--------------|-------------------|---------------|----------------|-----------|----------|--------------------|----------------------|-----------|
| Preterm | Preterm <7           | na                   | 18              | Note A       | na                | 1.37 (ml/min)  | 0.61 ± 0.05  | 5.7 ± 0.8  | na        | na                  | na                   | 13        |
| Term    | Term 7-28 b           | na                   | 14              |               | 4.45 (ml/min)     | 0.69 ± 0.08   | <0.05 NS      | 2.0 ± 0.5  | na        | na                  | na                   |           |
| 1.1 ± 0.22 kg body weight | na | 4.0 ± 1.6 | 1,103 ± 216 | 14 | 50 | 400 ± 56 | 23.0 | 0.51 ± 0.06 | 4.6 ± 1.1 | 115.9 ± 38.1 | 34.4 ± 12.1 | 24 |
| 2.6 ± 0.6 kg body weight | na | 3.5 ± 1.7 | 2,561 ± 607 | 15 | 50 | 392 ± 77 | 43.9 | 0.44 ± 0.07 | 3.4 ± 0.9 | 132.7 ± 37.7 | 38.1 ± 6.9 |           |

### Ceftazidime – Third-generation cephalosporins

| Comment | Gestational age (wk) | Postnatal age (days) | Body weight (g) | No. of Cases | Daily dose (mg/kg) | AUC (µg.h/ml) | CL (ml/min/kg) | Vd (L/kg) | t1/2 (h) | Peak conc. (µg/ml) | Trough conc. (µg/ml) | Reference |
|---------|----------------------|----------------------|-----------------|--------------|-------------------|---------------|----------------|-----------|----------|--------------------|----------------------|-----------|
| Intravenous | 35 a           | 6 a                  | 2,470 a         | 7            | 50                | na            | na             | 4.7 ± 1.5  | 109 ± 19.9 | 11.8 ± 4.1          |           | 20        |
| Intramuscular | 37 a           | 8 a                  | 2,860 a         | 9            | IM                | na            | na             | 3.8 ± 1.1  | 53.0 ± 22.4 | 8.9 ± 5.6           |           |           |
| p       | ---                | NS                  | <0.0001         | ---          | NS                | NS            | NS             | <0.01     | <0.01    | na                  | na                   |           |
| Preterm | <32                | <7                   | na              | 3            | 25                | 262 ± 46      | 1.08           | 0.34 ± 0.07 | 3.5 ± 0.4  | 73.8 ± 9.6          | 11.1 ± 8.0          | 17        |
| Term    | >37                | >7                   | na              | 5            | 25                | 177 ± 25      | 2.33           | 0.36 ± 0.08 | 2.0 ± 0.5  | 68.2 ± 9.6          | 22 ± 1.3            |           |
| p       | ---                | NS                  | <0.005          | NS           | NS                | NS            | NS             | <0.005    | <0.005   | NS                  | NS                   | <0.05     |

### Ceftriaxone – Third-generation cephalosporins

| Comment | Gestational age (wk) | Postnatal age (days) | Body weight (g) | No. of Cases | Daily dose (mg/kg) | AUC (µg.h/ml) | CL (ml/min/kg) | Vd (L/kg) | t1/2 (h) | Peak conc. (µg/ml) | Trough conc. (µg/ml) | Reference |
|---------|----------------------|----------------------|-----------------|--------------|-------------------|---------------|----------------|-----------|----------|--------------------|----------------------|-----------|
| 50 mg/kg | 5 term               | na                   | na              | 15           | 50                | 0.85          | 0.38 ± 0.13  | 5.8 ± 2.6  | 230 ± 64  | na                  | na                   | 29        |
| 75 mg/kg | 6 term               | na                   | na              | 15           | 75                | 0.93          | 0.39 ± 0.06  | 5.4 ± 2.1  | 295 ± 75  | na                  | na                   |           |
| Intravenous | 32 ± 4              | 1-60 b               | 1880 ± 860      | 12           | 50                | 0.28          | 0.33 ± 0.07  | 15.4 ± 5.6 | 153 ± 39  | 54 ± 22              | 30        |
| Intramuscular | These values refer | to the entire population | 18 cases.         | 6            | IM                | 0.28          | 0.32 ± 0.04  | 15.8 ± 5.8 | 120 ± 37  | 54 ± 19              |           |           |
| Preterm | na                  | 3.2 a                | 1164 a          | 10           | 50                | 1.0 (ml/min)  | 0.61 ± 0.02  | 7.7 ± 0.6  | 145 ± 18  | 66 ± 3.3              | 31        |
| Preterm | na                  | 6.7 a                | 1176 a          | 3            | 50                | 0.73          | 0.53 ± 0.03  | 8.4 ± 1.6  | 136 ± 8.9 | 71 ± 4.4              |           |           |
| Term    | na                  | 2.8 a                | 2670 a          | 9            | 50                | 1.8 (ml/min)  | 0.52 ± 0.04  | 7.4 ± 0.5  | 159 ± 9.1 | 74 ± 5.4              |           |           |
| Preterm | na                  | 22.5 a               | 2112 a          | 4            | 50                | 1.6 (ml/min)  | 0.50 ± 0.05  | 5.2 ± 0.6  | 173 ± 23 | 67 ± 12              |           |           |
The pharmacokinetic parameters of ceftazidime are summarized in Table 2. The ceftazidime concentration was measured after intravenous administration to seven neonates and after intramuscular administration to 9 infants. The ceftazidime concentrations after intravenous injection declined biexponentially, and the postdistributive phase occurred 30 to 60 min after administration. The peak ceftazidime concentration was 109±19.9 (intravenously) and 53.0±22.4 (intramuscularly; p<0.05). The t1/2 of ceftazidime was 4.7±1.5 (intravenously) and 3.8±1.1 (intramuscularly; NS).

McCracken et al described the pharmacokinetics of ceftazidime in three groups of neonates with gestational ages of ≤32, 33-37, and ≥38 weeks. CI increased with gestational age, whereas t1/2, AUC and the trough concentrations decreased with gestational age.

Blumer et al described ceftazidime’s pharmacokinetics and penetration into CSF in ten children aged 12 to 540 days. Cefazidime at 50 mg/kg was intravenously administered once per day. The t1/2 of ceftazidime was 1.8±0.8 h, which was 2- to 4-fold lower than that reported in neonates during the first week of life (see Table 2). The two youngest children, aged 12 and 23 days, had a t1/2 of 3.6 and 2.18 h, respectively. The CI of ceftazidime varied by more than 300%; such a large variation makes it inappropriate to report the average CI, so the data from Blumer et al are not shown in Table 2. In contrast, Vd showed little variation and ranged from 0.27 to 0.38 L/kg, with a mean ± SD of 0.34±0.07 L/kg. The ceftazidime concentrations in the CSF and serum were 4.7±2.5 and 145±30.4 μg/ml, respectively. The CSF-to-serum concentration of ceftazidime was 3.5±1.8%. The ratio of CSF to serum ceftazidime concentration showed a time-dependent increase, suggesting that ceftazidime was eliminated more slowly from the CSF than from the vascular compartment. The MIC of the isolated pathogens ranged from 0.0156 μg/ml (Neisseria meningitidis) to 0.125 μg/ml (Haemophilus influenzae, Type B).

Prenatal exposure to indomethacin resulted in significantly lower GFR and ceftazidime CI values. The Cl of ceftazidime was 0.46 ml/min/kg (n=23) in neonates who were prenatally exposed to indomethacin and 0.68 ml/min/mg (No=84) in infants who were not exposed to indomethacin (p<0.05). The Cl of ceftazidime increased with gestational age (r=0.83; p<0.001), whereas t1/2 showed an opposite trend (r= -0.54; p<0.001). The positive relationship between the CI of ceftazidime and the Cl of inulin (r=0.73; p<0.001) indicated that glomerular filtration had an important effect on the Cl of ceftazidime. The Cl of ceftazidime correlated with the reciprocal of the serum concentration of creatinine (r=0.72; p<0.001), suggesting that this compound may interfere with the renal Cl of ceftazidime.

The ceftazidime CI increased from days 3 to 10 of life (Table 2). Such increases are due to an increase in GFR. The inulin CI was 0.72 (day 3) and 0.91 ml/min (day 10; p<0.05). The Cl of ceftazidime correlated with GFR (r= 0.81; p<0.001). This correlation indicates the important role of GFR in the clearance of ceftazidime. The Vd of ceftazidime decreased between days 3 and 10 of life. During the first week of life, there was a significant decrease in extracellular water. Ceftazidime is mainly distributed in the extracellular water compartment, and a decrease of extracellular water may cause a decrease in the Vd during this period. Prenatal exposure to indomethacin prevented the pharmacokinetic
Modification seen from days three to ten of life. This may be explained by renal function’s dependence on postnatal changes in extracellular water and the GFR impairment associated with indomethacin use.

Once-daily versus twice-daily administration of ceftriaxone was studied by van den Anker et al. After 25 mg/kg twice daily, the trough concentration of ceftriaxone was 42.0 ± 13.4 µg/ml, which was higher than the target value of 10 µg/ml. After once-daily dosing, the trough concentration was 13.1 ± 4.7 µg/ml, higher than the target value of 10 µg/ml and higher than major neonatal pathogen MIC values such as those for Streptococcus agalactiae and Escherichia coli. Therefore, these authors suggested that once-daily 25 mg/kg ceftriaxone is the appropriate therapeutic schedule for ceftriaxone in the neonate. This administration schedule conflicts with the one suggested by Young and Mangum. They suggested administering 30 mg/kg of ceftriaxone every 8 or 12 h according to the postmenstrual and postnatal age. When the postmenstrual age is >45 weeks, ceftriaxone should be administered every eight hours.

Ceftriaxone. Ceftriaxone is contraindicated in neonates because it displaces bilirubin from albumin binding sites, resulting in a higher free bilirubin serum concentration with subsequent accumulation of bilirubin in the tissues. Even more dangerous is ceftriaxone’s interaction with calcium. This interaction precipitates calcium, which results in serious adverse effects.

Nonetheless, the literature on ceftriaxone was reviewed to provide a comprehensive study of cephalosporin use. The kinetic parameters of ceftriaxone are summarized in Table 2. The MIC<sub>90</sub> of ceftriaxone ranged between 0.06 and 2 µg/ml for Escherichia coli, Klebsiella species, Proteus species, Enterobacter species, and Staphylococcus aureus, whereas Enterococci and Listeria monocytogenes are resistant. Ceftriaxone reached CSF concentrations of 5.4 and 6.4 µg/ml after intravenous doses of 50 and 75 mg/kg, respectively, and the CSF-to-peak serum concentration was 2.2-2.3%. Sixty percent of ceftriaxone is eliminated by the kidneys, and Mullhall et al. have described the pharmacokinetics of this drug in the neonate (Table 2).

McCracken et al. stratified the kinetic parameters of ceftriaxone based on neonatal body weight. The longest t<sub>1/2</sub>, 7.7 to 8.4 h, was found in neonates weighing ≥1,500 g, compared with 5.2 to 7.4 h in those weighing >1,500 g. The shortest t<sub>1/2</sub> (3.5 and 4.8 h) was found in two neonates aged 45 to 33 days, respectively. Vd ranged between 0.50 and 0.61 l/kg; the smaller value was found in larger and older infants. Of nine neonates who received multiple ceftriaxone doses of 50 mg/kg every 12 h, five showed evidence of drug accumulation in the plasma. The concentrations of ceftriaxone increased from 20 to 208% (mean 82%) at 0.5 h and from 15 to 165% (mean 53%) at 6 h after dosing. The ceftriaxone concentration in randomly collected urine ranged from 113 to 3,350 µg/ml (median 618 µg/ml). Young and Mangum suggested administering 50 mg/kg every 24 h. To treat meningitis, they suggested a 100-mg/kg loading dose and then 80 mg/kg once daily.

Cefoperazone. The kinetic parameters of cefoperazone are summarized in Table 2. Gestational age correlated with Cl (r = 0.67; p = 0.01) and with a constant rate of elimination (K<sub>e</sub>; r = 0.57; p = 0.05), while t<sub>1/2</sub> decreased with advancing gestational age (r = -0.81; p = 0.001). Rosenfeld et al. studied the pharmacokinetics of cefoperazone (50 mg/kg) in 25 infants with a postnatal age of 1 to 2 days. The neonates were divided into three groups according to their gestational age. These authors repeated the cefoperazone treatment in 14 neonates aged 5 to 7 days, and the kinetic parameters were similar to those obtained at a postnatal age of 1 to 2 days. The percentage of the cefoperazone dose excreted in the urine on days 1 and 2 after birth was highest in the most premature patients (55%) but was not statistically different from that of full-term infants (37%). In infants 5 to 7 days old, cefoperazone excretion decreased in the full-term neonates (27%) and was 55% in the most premature infants (p < 0.03). These data suggest that cefoperazone is partially metabolized and that its rate of metabolism depends on neonatal maturation. In adults, 69% of cefoperazone administered orally is eliminated by hepatic routes.

A study based on seven neonates with body weights ranging from 1,540 to 3,600 g determined that cefoperazone penetrates the CSF. The cefoperazone concentration (µg/ml) in the CSF and serum was 5.3 ± 3.6 and 89 ± 58, respectively. The CSF-to-serum ratio was 10.9 ± 9.6% and ranged from 1.4 to 31.7%.

Ceftizoxime. The kinetic parameters of ceftizoxime are summarized in Table 2. The pharmacokinetics of ceftizoxime were studied in 52 infants whose postnatal age ranged from 0.1 to 189 days, t<sub>1/2</sub> diminished steadily as the postnatal age increased, whereas Cl showed the opposite trend. In this study, Vd remained relatively constant, and ceftizoxime was excreted essentially unchanged via the kidney.

Fourth-generation cephalosporins

Cefepime. The kinetic parameters of cefepime are summarized in Table 3. The serum creatinine concentration was negatively correlated (r = -0.79) with cefepime Cl in neonates. The serum concentration of creatinine was a strong predictor of cefepime Cl. The relationship between cefepime Cl and gestational age was not significant. The maturation of the renal excretory function is an important dosing determinant for cephalosporins, including cefepime. In premature infants, renal function is impaired. Because cefepime is mainly excreted unchanged, the premature and

### Table 3 - Demographic data of the neonates and pharmacokinetic parameters of the fourth-generation cephalosporin cefepime. Figures are the mean ± SD unless otherwise stated.

| Gestational age (wk) | Postnatal age (days) | Body Weight (g) | No. of cases | Daily dose (mg/kg) | CI (mL/min/kg) | Vd (L/kg) | t<sub>1/2</sub> (h) | Peak conc. (µg/ml) | Trough conc. (µg/ml) | Reference |
|---------------------|---------------------|-----------------|--------------|-------------------|---------------|-----------|-------------|------------------|------------------|-----------|
| 30 ± 5.3            | 14.7 ± 14.5         | 1,910 ± 1,040   | 54           | 50 ± 2            | 1.1           | 0.43 ± 0.13 | 4.9 ± 2.1  | 89 ± 27          | 18 ± 10          | 38        |
| na                  | 2 to 6 months       | na              | 8            | 50 ± 3            | 2.7           | 0.43 ± 0.11 | 1.9 ± 0.5  | 184 ± 38         | 6 ± 7            | 39        |
| 31 ± 3              | 21.8 ± 14           | 1,400 ± 400     | 31           | 50 ± 2            | 1.2           | 0.41 ± 0.12 | 4.3 ± 1.8  | 120 ± 38         | 18 ± 13          | 40        |

na = not available.
term neonates clear cefepime more slowly than more mature infants. In neonates, the cefepime Cl value was approximately 40% of that of more mature infants, which results in a longer $t_{1/2}$ and a higher trough concentration. Vd was greater in infants with less than 30 weeks of postconceptual age. This is consistent with the greater total body water content in the extremely premature neonate.

Reed et al.\textsuperscript{38} described the pharmacokinetics of cefepime in 37 infants and children aged between 2 months and 16 years. The data were grouped by age; the youngest patients ranged between two and six months of age, and the pharmacokinetic parameters of cefepime in these patients are reported in Table 3. Ninety percent of cefepime was recovered in the urine during 24-h urine collection; thus, the elimination of cefepime is in large part via the kidneys. The data for cefepime reveal disposition parameters similar to those of third-generation cephalosporins, including linearity over a broad dose range (250-2,000 mg), limited disposition and Cl mainly by the kidneys.

Lima-Rogel et al.\textsuperscript{40} compared their own results on the pharmacokinetics of cefepime in neonates with those of Capparelli et al.\textsuperscript{38} and Reed et al.\textsuperscript{39} The kinetic parameters of cefepime measured by Lima-Rogel et al.\textsuperscript{40} and those of Capparelli et al.\textsuperscript{38} were obtained in infants with similar demographic data, and $t_{1/2}$ and Cl were comparable in these two studies. Reed et al.\textsuperscript{39} described the pharmacokinetics of cefepime in older infants and children. In this last study, $t_{1/2}$ was one-half and Cl was double the values in the neonates.

Information on the penetration of cephalosporins in the CSF is limited. Table 4 summarizes the concentrations of cefotaxime, ceftazidime, ceftriaxone, cefoperazone, and cefepime in the CSF and serum and the CSF-to-serum ratio. Information on the penetration in the CSF is available only for these cephalosporins. A relevant CSF-to-serum ratio was observed for cefotaxime\textsuperscript{13} and it was 45±12%. Another relevant penetration rate in the CSF was observed for cefoperazone,\textsuperscript{24} which was 10.9±9.6%. This figure seems to be overestimated, as it ranged from 1.4% to 37.1%. The rate of penetration of cephalosporins in the CSF was variable. In two preterm infants, the CSF-to-serum ratio was 30% and 87%, whereas in 7 term infants, it ranged from 3.6% to 59%, with a mean±SD of 16.7±21.4%. Table 4 shows the data for all nine neonates.

**DISCUSSION**

A common feature in the reviewed literature is the remarkable interindividual variability of the kinetic parameters of cephalosporins in the neonate. Such variability is due to renal maturation, as cephalosporins are fairly water soluble and are mainly eliminated with the urine.

The pharmacokinetic parameters of cephalosporins are development dependent; the $t_{1/2}$ of cefotaxime,\textsuperscript{13,14} ceftazidime\textsuperscript{24-26} and ceftizoxime\textsuperscript{27} decrease with increasing gestational and postnatal age, whereas Cl shows an opposite trend. With prenatal and postnatal maturation, GFR increases, and consequently, the Cl of drugs that are mainly eliminated by kidneys increases.\textsuperscript{41,42} Vd is only slightly influenced by neonatal maturation, although it tends to decrease with the maturation of the neonate. This has been observed for cefotaxime.\textsuperscript{20,24} Preterm infants have a higher water content than term infants,\textsuperscript{40} and because cephalosporins are fairly water soluble, they are distributed at a larger volume in preterm infants than in term infants.

The hypersensitivity, resistance and toxicology of cephalosporins have been studied in adults, but little is known about these characteristics in the neonate. Cephalosporin resistance may be related to the drug’s inability to reach its sites of action, alterations in the penicillin-binding proteins that are the targets of cephalosporins or hydrolysis of the β-lactam ring by β-lactamase.\textsuperscript{4} The most common side effects of cephalosporins are hypersensitivity reactions. The reactions appear to be identical to those caused by penicillins and may be related to the shared β-lactam structure of both groups of antibiotics. Immediate reactions, such as anaphylaxis, bronchospasm, and urticaria, are typically observed.\textsuperscript{4} The cephalosporins have been implicated as potentially nephrotoxic agents, although they are not nearly as toxic to the kidneys as the aminoglycosides or polymyxins. In adults, renal tubular necrosis has followed the administration of cephaloridine in doses greater than 4 g/day.\textsuperscript{4}

With the exception of cefotaxime\textsuperscript{15,16} and cefoperazone,\textsuperscript{34} which are partially metabolized, cephalosporins are mostly eliminated by the renal route, and maturation of the excretory renal function increases with development. Cl correlates with gestational age for cefotaxime,\textsuperscript{15} cefoperazone,\textsuperscript{32} and ceftazidime.\textsuperscript{23} The Cl of cefotaxime is 2- to 3-fold higher in term than preterm infants.\textsuperscript{13,14} With increasing Cl, $t_{1/2}$ clearly decreases. The Cl of ceftazidime negatively correlates with the reciprocal of serum concentration of creatinine; thus, the serum creatinine concentration negatively influences the Cl of ceftazidime.\textsuperscript{23}

Little is known about the AUC, although this parameter for cefotaxime is similar in preterm and term infants.\textsuperscript{14} In contrast, the AUC for ceftazidime is greater in neonates with a gestational age ≥32 weeks than in term infants.\textsuperscript{21} This

| Drug              | Daily dose (mg/kg) | Drug concentration in CSF (μg/ml) | Drug concentration in serum (μg/ml) | % CSF-to-serum ratio | Reference |
|-------------------|--------------------|-----------------------------------|------------------------------------|----------------------|-----------|
| Cefotaxime*       | 50–20              | 18.2±7.4                          | 38.6±10.3                          | 45±12                | 13        |
| Ceftazidime *     | 50                 | 4.7±2.5                           | 145±30.4                           | 3.5±1.8              | 22        |
| Ceftriaxone       | 75                 | 6.5 b                             | 295±64                             | 2.2 b                | 29        |
| Ceftriaxone*      | 50                 | 5.4 b                             | 230±64                             | 2.3 b                | 29        |
| Cefoperazone *    | 50                 | 5.3±3.6                           | 89±58                              | 10.9±9.6             | 34        |
| Cefepime *        | 50–20              | 4.7±5.3                           | 32.7±23.1                          | 25.8±29.8            | 43        |

*Infants with meningitis.

The CSF-to-serum ratio ranged from 1.4 to 31.7%.

| Drug              | Daily dose (mg/kg) | Drug concentration in CSF (μg/ml) | Drug concentration in serum (μg/ml) | % CSF-to-serum ratio | Reference |
|-------------------|--------------------|-----------------------------------|------------------------------------|----------------------|-----------|
| Cefotaxime*       |                    |                                   |                                    |                      |           |
| Ceftazidime *     |                    |                                   |                                    |                      |           |
| Ceftriaxone       |                    |                                   |                                    |                      |           |
| Ceftriaxone*      |                    |                                   |                                    |                      |           |
| Cefoperazone *    |                    |                                   |                                    |                      |           |
| Cefepime *        |                    |                                   |                                    |                      |           |

*The CSF-to-serum ratio ranged from 1.4 to 31.7%.

| Drug              | Daily dose (mg/kg) | Drug concentration in CSF (μg/ml) | Drug concentration in serum (μg/ml) | % CSF-to-serum ratio | Reference |
|-------------------|--------------------|-----------------------------------|------------------------------------|----------------------|-----------|
| Cefotaxime*       |                    |                                   |                                    |                      |           |
| Ceftazidime *     |                    |                                   |                                    |                      |           |
| Ceftriaxone       |                    |                                   |                                    |                      |           |
| Ceftriaxone*      |                    |                                   |                                    |                      |           |
| Cefoperazone *    |                    |                                   |                                    |                      |           |
| Cefepime *        |                    |                                   |                                    |                      |           |

*The CSF-to-serum ratio ranged from 1.4 to 31.7%.
finding is due to the reduced renal excretory function in preterm infants compared with term infants. In premature subjects, the Cl of ceftazidime is reduced; therefore, the cephalosporin serum concentration slowly decreases, and AUC tends to increase.

Most of the available information about the kinetics of cephalosporins deals with the third generation of these antibiotics. A considerable body of information is available on cephalosporins, cefazidime, and cefotaxime.

The Cl of ceftazidime increases between days 3 and 10 of life. This increase is due to the increase in GFR. The Cl of ceftazidime is also correlated with GFR (r = 0.81; p < 0.001). This correlation indicates the important effect of GFR on the clearance of ceftazidime Cl. Intravenous administration of cephalosporins yields double the peak concentration of intramuscular administration.

Ceftriaxone is active against Escherichia coli, Klebsiella species, Proteus species, Enterobacter species, and Staphylococcus aureus. Cefepime is a fourth-generation cephalosporin and little is known about this drug, as it is the latest cephalosporin to enter clinical use. Cefepime penetrates the blood-brain barrier well.

Meningitis can be treated with cephalosporins, so the penetration of these drugs in the CSF is important. Information on the concentration of cephalosporins in CSF is available for cefotaxime, ceftazidime, ceftriaxone, cefoperazone, and cefepime. Cefotaxime reaches a considerable CSF concentration, and the CSF-to-serum concentration ratio is relevant. Only one study is available on the penetration of cefepime in CSF.

The concentration of this drug varies considerably in serum and CSF, and consequently, the CSF-to-serum ratio ranges widely.

The penetration of other cephalosporins into the CSF should be studied, and we feel that further research is required to ensure that the doses recommended for treating sepsis in neonates are entirely evidence-based.

ACKNOWLEDGEMENTS

This work was supported by the Ministry of Science and Technological Research (Rome, Italy).

REFERENCES

1. Neu HC. In vitro activity of ceftazidime, a β-lactamase stable cephalosporin. J Antimicrob Chemother. 1981;8(Suppl 1):131-4.
2. Williams JD. Classification of cephalosporins. Drugs. 1987;34(Suppl 2):15-21.
3. Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am. 1995;79:705-19.
4. Petri WA Jr. Penicillins, cephalosporins, and other β-lactam antibiotics. In: "The pharmacological basis of therapeutics". Brunton LL, Lazo JS, Parker KL editors. 11th edition, 2006 pp 1127-1154. New York USA.
5. Martin E, Fanconi S, Kalm P, Zwingelstein C, Crevoisier C, Ruch W, et al. Ceftriaxone—bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr. 1993;152:530-4.
6. Gilian JM, Conard V, Dalmasso C, Palis C. Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of free' bilirubin and erythrocyte-bound bilirubin. J Antimicrob Chemother. 1987;19:823-9.
7. Steadman E, Raisch DW, Bennett CL, Esterly JS, Becker T, Postelnick M, et al. Evaluation of a potential clinical interaction between ceftriaxone and calcium. J Antimicrob. Agents. Chemother. 2010;54:1534-40.
8. Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991;100:1665-70.
9. Young TE, Mangum B. Antimicrobials pp 1-99. Neotax. A Manual of Drugs used in neonatal care. Edition 23, Thomson Reuters, Montvale 07645, New Jersey, USA 2010.
10. Deguchi Y, Koshida R, Nakashima E, Watanabe T, Toniguchi N, Ichimura F, et al. Interindividual differences in volume of distribution of cefotaxime in ewborn infants and its prediction based on physiological pharmacokinetic concepts. J Pharmacol. 1986;77:674-8, doi: 10.1002/j.1097-0032.1986.tb00780.x.
11. Regazzi MB, Chirico G, Cristiani D, Rondini G, Rondanelli R. Cefotaxim in newborns. A clinical and pharmacokinetics study. Eur J Clin Pharmacol. 1983;25:507-9.
12. Relund M, Pettau O. Pharmacokinetics and clinical efficacy of cefuroxime in the newborn period. Proc roy Soc Med. 1977;70:179-82.
13. Kafetzis DA, Brater DC, Kapiki AN, Papas CV, Delaocious H, Papadootos C. Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics. J Pediatr. 1982;100:483-9.
14. McCracken GH, Threlkeld NA, Thomas ML. Pharmacokinetics of cefotaxime in newborn infants. Antimicrob Agents Chemother. 1982;21:683-4.
15. Gouyon JB, Pechinot A, Safran C, Chretien P, Sandre D, Kaminzcer A. Pharmacokinetics of cefotaxime in preterm infants. Dev Pharmacol Ther. 1986;9(29-34).
16. Crooks J, White LO, Burville LJ, Speidel BD, Reeves DS. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in neonates. J Antimicrob Chemother. 1984;14(Suppl. B):97-101.
17. Arundel Y, Brin F, Jacob-Aigrain F, Kasse MC, Chretien P, Criqui C, et al. Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newborn. Diagn Microbiol Infect Dis. 1989;12:87-91, doi: 10.1016/0732-8893(89)90051-5.
18. Kappes GL, Jacobs RF, Thomas BR, Darville TL, Trang JM. Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates. J Pediatrics. 1989;114:461-7, doi: 10.1016/S0022-3476(89)80573-9.
19. Ahsmaj MJ, Wildschut ED, Tibboel D, Mathot RA. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2010;54:1734-41, doi: 10.1128/AAC.01696-09.
20. Bongianni A, Rizzo M, Cappi MS, Assale BM. Comparison of the concentrations of cefotaxime in the serum of newborns after intravenous and intramuscular administration. Antimicrob Agents Chemother. 1985;24:955-6.
21. McCracken GH Jr, Threlkeld N, Thomas ML. Pharmacokinetics of cefotaxime in newborn infants. Antimicrob Agents Chemother. 1984;26:583-4.
22. Blumer H, Aronoff SC, Myers CM, O'Brien CA, Klinger JD, Reed MD. Pharmacokinetics and cerebrospinal fluid penetration of cefotaxime in children with meningitis. Dev Pharmacol Ther. 1985;8:219-31.
23. van den Anker JN, Schoemaker RC, Hop WC, van der Heijden BJ, Weber A, Sauer PJ, et al. Cefotaxime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther. 1995;58:650-9, doi: 10.1002/1870-2926(1995)90021-7.
24. van den Anker JN, Hop WC, Schoemaker RC, van der Heijden BJ, Neijens HJ, de Groot R. Cefotaxime pharmacokinetics in preterm infants: effect of postnatal age and extra uterine exposure to indomethacin. Br J Clin Pharmacol. 1995;40:439-43.
25. van den Anker JN, Schoemaker RC, van der Heijden BJ, Broere HM, Neijens HJ, de Groot R. Once-daily versus twice-daily administration of cefotaxime in the preterm infant. Antimicrob Agents Chemother. 1995;39:2048-50.
26. Gentry LO. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of cefotaxime. Pharmacotherapy. 1985;5:254-69.
27. Neu HC. Pathophysiologic basis for the use of third-generation cephalosporins. Am J Med. 1990;88(Suppl. 4A):3S-11S, doi: 10.1016/0002-9343(90)90321-4.
28. Bint AJ, Yeoman P, Kilburn P, Anderson E, Stansfield E. The in vitro activity of cefotaxime compared with that of the other cephalosporins. J Antimicrob Chemother. 1981;8(Suppl B):47-51.
29. Steele RW, Eyre LB, Bradshaw RW, Wennefeld RE, Patel IH, Spierer J. Pharmacokinetics of ceftriaxone in pediatric patients with meningitis. Antimicrob Agents Chemother. 1983;21:191-4.
30. Mulhall A, de Louvois J, James J. Pharmacokinetics of ceftriaxone and desacetylceftriaxone in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1984;26:583-4.
31. McCracken GH Jr, Threlkeld N, Thomas ML. Pharmacokinetics of ceftriaxone in newborn infants. Antimicrob Agents Chemother. 1984;26:583-4.
34. Rosenfeld WN, Evans HE, Batheja R, Jhaveri RC, Vohra K, Khan AJ. Pharmacokinetics of cefoperazone in full-term and premature neonates. Antimicrob Agents Chemother. 1983;23:866-9.

35. Brogden RN, Carmine A, Heel RC, Morley PA, Speight TM, Avery GS. Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy. Drugs. 1981;22:423-60, doi: 10.2165/00003495-198122060-00002.

36. Reed MD, Gooch WM 3rd, Minton SD, Tanaka-Kido J, Santos JJ, Yamashita TS, et al. Ceftizoxime disposition in neonates and infants during the first six months of life. DICP. 1991;25:344-7.

37. Cutler RE, Blair AD, Burgess ED, Parks D. Pharmacokinetics of ceftizoxime. J Antimicrob Chemother. 1982;10(Suppl C):91-7.

38. Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J, Moya F. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother. 2005;49:2760-6, doi: 10.1128/AAC.49.7.2760-2766.2005.

39. Reed MD, Yamashita TS, Knupp CK, Veazey JM Jr, Blumer JL. Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children. Antimicrob Agents Chemother. 1997;41:1783-7.

40. Lima-Rogel V, Medina-Rojas EL, Del Carmen Milán-Segovia R, Noyola DE, Nieto-Aguirre K, et al. Population pharmacokinetics of cefepime in neonates with severe nosocomial infection. J Clin Pharmacol Ther. 2008;33:295-306, doi: 10.1111/j.1365-2710.2008.00912.x.

41. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet. 1990;19:280-318, doi: 10.2165/00003088-199019040-00003.

42. de Hoog, Mounton JW, can den Anker JN. Vancomycin. Pharmacokinetics and administration regimen in neonates. Clin Pharmacokinet. 2004;43:417-40, doi: 10.2165/00003088-200443070-00001.

43. Ellis JM, Rivera L, Reyes G, Castillo F, Marte P, Tejada M, et al. Cefepime cerebrospinal fluid concentrations in neonatal bacterial meningitis. Ann Pharmacother. 2007;41:900-1, doi: 10.1345/aph.1H585.